BAUSCH Health

Salix To Highlight New Data Across Its Portfolio Of Products At Digestive Disease Week 2020 Virtual Meeting

April 30, 2020

BRIDGEWATER, N.J., April 30, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its gastroenterology business, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases, today announced that fourteen new scientific posters featuring research and data spanning Salix's GI portfolio – including rifaximin, plecanatide, methylnaltrexone bromide and PEG-3350, electrolytes and ascorbate for oral solution – will be accessible on Digestive Disease Week®'s (DDW) ePosters and ePapers free, online portal beginning Saturday, May 2, 2020.

"R&D is at the core of our business strategy and the driver behind our ongoing commitment to shape the future of GI," said Joseph C. Papa, chairman and CEO, Bausch Health. "We look forward to sharing what we believe is compelling GI data and continuing to engage in productive scientific exchange to drive the development of new, innovative solutions for patients with unmet needs."

The full list of research to be released via the DDW online portal includes:

- *Chang, Christopher. "A Pooled Analysis of Two Phase 3, Placebo-Controlled Studies Assessing the Impact of Colonoscopy Timing on Rifaximin Efficacy in Irritable Bowel Syndrome with Diarrhea."*
- *Rao, Satish S.C. "Rifaximin Is Efficacious for the Treatment of Irritable Bowel SyndromeWith Diarrhea in Adults Previously Treated with Other IBS Medications."*
- *Bajaj, Jasmohan S. "Lactulose Withdrawal Can Potentiate Breakthrough Overt Hepatic Encephalopathy in Patients Controlled with Rifaximin Plus Lactulose Therapy: A Post Hoc Analysis of a Randomized Controlled Trial."*
- *Kakiyama, Genta. "Rifaximin Soluble Solid Dispersion Tablets Modify Gut Microbial Function, as Shown by Increased Fecal Secondary Bile Acid Levels Compared with Placebo, in Patients with Early Decompensated Cirrhosis."*
- *Bharucha, Adil E. "Plecanatide for Patients with Chronic Idiopathic Constipation and Irritable Bowel Syndrome–Constipation: Analysis of Abdominal Pain from Four Randomized Phase 3 Clinical Trials."*
- *Moshiree, Baharak. "Acid Suppression Therapy Does Not Affect the Efficacy and Safety Profile of Plecanatide: A Patient-Level Pooled Analysis of Two Large Randomized Controlled Trials in Chronic Idiopathic Constipation."*
- *Brenner, Darren. "Plecanatide for Patients with Chronic Idiopathic Constipation and Irritable Bowel Syndrome–Constipation: Analysis of Symptoms' Responses by Baseline Bloating Severity from Four Randomized Phase 3 Clinical Trials."*
- *Menees, Stacy. "Safety and Efficacy Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome–Constipation in Patients Aged 65 Years or Older."*

- *Webster, Lynn. "Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis."*
- *Farchadi, David. "Cumulative Laxation Response with Methylnaltrexone: Implications for Hospitalized Patients with Advanced Illness and Opioid-Induced Constipation."*
- *Mehta, Neel. "Attrition of Treatment-Emergent Adverse Events by Methylnaltrexone in Patients with Chronic Noncancer Pain and Opioid-Induced Constipation."*
- *Caffrey, Rebecca. "Methylnaltrexone and Rifaximin Treatments Significantly Improve Chronic "Leaky Gut" in a Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease."*
- *Cash, Brooks. "Efficacy of 1 L NER1006 Bowel Preparation for Colonoscopy in Adults with Diabetes: A Pooled Analysis of Two Randomized, Phase 3 Studies."*
- *Schoenfeld, Philip. "Adenoma Detection Rates with 1 L NER1006 Bowel Preparation Exceed Minimum Threshold Recommendations in Colonoscopy Screening Population and NER1006 Demonstrates Overall Bowel Cleansing Success Regardless of Colonoscopy Indication."*

About Salix

Salix is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For over 30 years, Salix has licensed, developed, and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists, and primary care. Salix is headquartered in Bridgewater, New Jersey.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at
www.bauschhealth.com
.

Forward-looking Statements

This news release contains forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Company's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on the Company, including but not limited to its supply chain, third party suppliers, project development timelines, and costs (which may increase) and revenue and margins (both of which may decrease). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Investor Contact:	Media Contacts:
Arthur Shannon	Lainie Keller
arthur.shannon@bauschhealth.com	lainie.keller@bauschhealth.com
514-856-3855	908-927-1198
(877) 281-6642 (toll free)	
	Karen Paff
	karen.paff@salix.com
	908-927-1190

View original content to download multimedia: http://www.prnewswire.com/news-releases/salix-to-highlight-new-data-across-its-portfolio-of-products-at-digestive-disease-week-2020-virtual-meeting-301049876.html

SOURCE Bausch Health Companies Inc.

Investor Inquiries
ir@bauschhealth.com
877-281-6642
514-856-3855 (Canada)

Media inquiries
Corporate.communications@bauschhealth.com
848-264-0934

LEGAL NOTICE PRIVACY POLICY

EMAIL ALERTS EMAIL PAGE RSS FEED

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

Powered by SITECORE